Indication Global
Market Size
Pre
Clinical
Phase
Ib
Phase
IIb
EU Conditional
Marketing Approval
Post EU
Marketing
US Phase 3
Organ failure associated with Sepsis $33B   Completed Phase IIb Initiation Q1 2021    
               
ARDS associated with severe/critical COVID-19 / Non-COVID-19 ARDS $1B (COVID)
$15B (ARDS)
  Completed
COVID-19
Phase II Ongoing
COVID-19
   
               
Solid tumors in combination with immune checkpoints $4B   Q3 2021      
               

Recent Publications